Ekso Bionics Holdings, Inc. — FY2022 Form 10-K
Entity and period: The supplied filing is for Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), not Chronoscale Holdings Corp. It covers the fiscal year ended December 31, 2022; comparisons are with FY2021. The financial statements received an unqualified audit opinion. The auditor identified revenue recognition, including allocation of contract prices among performance obligations, as a critical audit matter.
Business context
Ekso designs and sells exoskeletons for medical rehabilitation and industrial uses. Its medical portfolio includes EksoNR and, following its December 5, 2022 acquisition of Parker Hannifin’s Human Motion and Control business, the Ekso Indego Therapy and Personal products. EksoWorks primarily sells the EVO industrial exoskeleton. The acquisition expanded the medical portfolio and added manufacturing, distribution and technology assets; acquired-business revenue contributed only $103,000 in 2022 because the transaction closed late in the year.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $12.9 million | $11.2 million |
| Gross profit / margin | $6.2 million / 48% | $6.7 million / 60% |
| Operating expenses | $21.8 million | $20.6 million |
| Operating loss | $15.6 million | $13.8 million |
| Net loss | $15.1 million | $9.8 million |
| Net loss per share, basic | $1.16 | $0.80 |
| Cash used in operating activities | $14.7 million | $11.2 million |
Medical-segment revenue was $11.8 million, up from $9.8 million; industrial revenue was $1.1 million, down from $1.5 million. Revenue growth reflected higher medical-device sales, while industrial sales weakened as Ekso refocused its market approach. Gross margin contracted 12 percentage points, driven by supply-chain inflation, higher labor costs and lower average selling prices.
At year-end, cash and restricted cash totaled $20.5 million, including $2.0 million restricted under the bank-loan covenant; management cited approximately $18.5 million of unrestricted cash. Working capital was $21.8 million, down from $40.9 million. Total assets were $40.9 million and total liabilities $15.5 million. Notes payable had a $6.1 million carrying value: a $2.0 million Pacific Western Bank term loan due August 2023 and a Parker Hannifin note with $5.0 million face value, zero stated interest and installments beginning December 2023. The bank loan is secured by substantially all assets other than intellectual property.
Cash and restricted cash declined from $40.4 million to $20.5 million. Investing activities used $5.2 million, mainly for the $5.0 million HMC acquisition. The company raised no cash through financing activities in 2022; FY2021 financing provided $38.7 million. Year-end deferred revenue was $2.2 million, and non-cancellable subscription backlog was $2.3 million.
Material changes, outlook and risks
- Acquisition and product focus: The HMC acquisition cost $5.0 million in cash plus a $5.0 million subordinated note. Its preliminary purchase-price allocation included $5.2 million of intangible assets and $431,000 of goodwill. Ekso discontinued EksoVest and EksoZeroG during 2022 and prioritized EVO within industrial products.
- Funding and going concern: Ekso has a $223.9 million accumulated deficit and has generated recurring operating losses and negative operating cash flows. The filing says expected future losses and need for funding raise substantial doubt about ability to continue as a going concern within one year after issuance. Management considered expense reductions and other plans probable and concluded they would alleviate that doubt for at least 12 months; management also expects long-term cash needs to require external financing. It warned that additional equity financing is not assured.
- Near-term obligations: The $2.0 million bank-loan principal was due in August 2023. The Parker note begins quarterly payments in December 2023. Management said it believed cash on hand was sufficient for requirements for 12 months from issuance, subject to its assumptions and plans.
- No quantified guidance: The filing provides no specific revenue, earnings or margin guidance. Management expects operating cash requirements to exceed cash generated by operations and anticipates higher sales, marketing and R&D costs following the acquisition. It described efforts to expand contract manufacturing and expected most EVO production to shift to its Malaysian partner in 2023.
- Principal operating risks: Hospital budget pressure, lengthy sales cycles, uncertain reimbursement and adoption, competition, supply-chain constraints, inflation, manufacturing execution and product liability could weigh on results. Ekso also cited foreign-exchange exposure: 44% of FY2022 revenue was denominated in foreign currencies, and a hypothetical 10% strengthening of the U.S. dollar would have reduced revenue by $0.6 million.
- Regulatory and unusual items: None of Ekso’s products had been approved under the EU Medical Device Regulation as of year-end; the company also reported a Canadian marketing restriction pending a renewed device license. FY2022 net loss included a $1.3 million non-cash gain from revaluing warrant liabilities; FY2021 included a $1.1 million PPP-loan forgiveness gain and a larger $4.0 million warrant revaluation gain. A related-party settlement recorded $205,000 of 2022 expense and a $325,000 liability, payable over 14 months. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.
Investor verification priorities
- Confirm post-year-end cash burn, financing raised or available, and whether management’s liquidity plans met the stated 12-month needs.
- Verify repayment or refinancing of the August 2023 bank loan, compliance with its covenants, and the timing and impact of Parker-note payments.
- Track HMC integration, acquired-product sales, preliminary purchase-price adjustments, and the economics of the acquired licenses and distribution arrangements.
- Assess whether revenue growth can recover gross margin from 48%, particularly as inflation, contract manufacturing and product mix affect costs.
- Check progress on EU MDR certification and Canadian registration, as well as reimbursement, clinical adoption and sales-cycle trends.
- Review dilution risk from potential equity financing and outstanding options, RSUs and warrants; confirm that the reported share counts and any subsequent issuances are current.